Diagnostic Yield and Cost-Benefit When Utilizing Clinical Whole Genome Sequencing

Genet Test Mol Biomarkers. 2022 May;26(5):253-254. doi: 10.1089/gtmb.2022.0096. Epub 2022 May 20.

Authors

Vani Rajan¹, Sharon F Terry¹, Jessica Green¹, Julia Ortega¹

Affiliation

¹ Genetic Alliance, Damascus, Maryland, USA.

PMID: 35593883
DOI: 10.1089/gtmb.2022.0096

No abstract available

MeSH terms

Cost-Benefit Analysis
Exome Sequencing
Humans
Whole Genome Sequencing*